<DOC>
	<DOCNO>NCT00906594</DOCNO>
	<brief_summary>The purpose study evaluate additive effect dorzolamide/timolol fix combination patient undergoing monotherapy latanoprost .</brief_summary>
	<brief_title>Additive Intra-ocular Pressure Reduction Effect Fixed Combination Maleate Timolol 0.5 % /Dorzolamide 2 % Monotherapy With Latanoprost Patients With Elevated Intra-ocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>All patient least 18 year old , unilateral bilateral openangle glaucoma ( define IOP &gt; 21 mmHg , mean three consecutive measurement , time day , moment glaucoma diagnosis ) ocular hypertension ( IOP &gt; 25 mmHg , mean three consecutive measurement , anytime day , moment diagnosis ) . Glaucoma define reproducible glaucomatous visual field defect base GHT outside normal limit and/or PSD low 0,5 % glaucomatous change optic disc associate elevated IOP . A visual acuity ( ETDRS ) 20/80 good require randomization . Included woman childbearing potential , pregnancy , systemic contraindication betablocker therapy , argon laser trabeculoplasty three month screen visit , history filtering surgery , ocular surgery uveitis three month screen visit , hypersensitivity compound study drug , concomitant use experimental drug , condition treatment betablocker contraindicate abnormal and/or ocular condition symptom would prevent study participation , accord judgment investigator . The use systemic betablocker , need , allow consider exclusion criterion . Latanoprost nonresponders define low 15 % IOP reduction runin period latanoprost monotherapy exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>